Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044005 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of Drug to Treat Schizophrenia
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT00044005 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 98 participants.
The verdict
NCT00044005, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
Interventions
- DRUG Lurasidone 40 mg
- DRUG Lurasidone 20 mg
- DRUG Lurasidone 80mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2002-09 |
| Est. Completion | 2003-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044005
The ClinicalTrials.gov registry entry for NCT00044005 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lurasidone 40 mg is the first listed.
NCT00044005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044005 about?
NCT00044005 is a clinical study titled "Safety and Tolerability Study of Drug to Treat Schizophrenia". The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
What is the current status of trial NCT00044005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2002-09. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00044005?
The interventions under investigation include: Lurasidone 40 mg (DRUG), Lurasidone 20 mg (DRUG), Lurasidone 80mg (DRUG).
Who is sponsoring clinical trial NCT00044005?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.